Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

This study is testing a targeted alpha particle radiotherapy — a type of precision radiation that delivers intense, short-range radiation directly to cancer cells — in patients with metastatic uveal melanoma (a rare cancer that starts in the eye and commonly spreads to the liver). This cancer has very limited effective treatment options, and this approach aims to target cancer cells while sparing surrounding healthy tissue. **You may be eligible if...** - You are 18 or older with confirmed metastatic uveal melanoma - Your cancer has progressed after at least one prior treatment - You have measurable cancer on scans (per RECIST 1.1) - You are in good general health (ECOG 0–1) - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have not tried any prior treatment for metastatic uveal melanoma - Your blood counts, liver, or kidney function are below required thresholds - You have uncontrolled infections or serious medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.